Arcus Biosciences Financial Statements
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcus Biosciences revenue and earnings
In fiscal 2025, Arcus Biosciences generated $247.0 million in revenue, down 4.3% from fiscal 2024, its first annual decline since 2022. Arcus Biosciences reported a net loss of $353.0 million, compared with a loss of $283.0 million a year earlier. Operating margin was -156.3%.
Diluted earnings per share came in at -$3.29. Over the last 5 fiscal years, RCUS's revenue has grown at a 25.9% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Arcus Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 247.00M | 258.00M | 117.00M | 112.00M | 383.00M | 78.00M | 15.00M | 8.35M | 1.41M | — |
| Revenue growth (YoY) | -4.26% | +120.51% | +4.46% | -70.76% | +391.03% | +420.00% | +79.58% | +491.15% | — | — |
| Operating Expenses | 633.00M | 588.00M | 457.00M | 392.00M | 329.00M | 202.00M | 103.71M | 63.21M | 54.85M | 18.18M |
| Research & Development | 523.00M | 448.00M | 340.00M | 288.00M | 257.00M | 159.00M | 78.48M | 49.65M | 47.22M | 14.25M |
| Operating Income | -386.00M | -330.00M | -340.00M | -280.00M | 54.00M | -124.00M | -88.71M | -54.86M | -53.44M | -18.18M |
| Interest Expense | 8.00M | 4.00M | 2.00M | 2.00M | — | — | — | — | — | — |
| Other Income (Expense) | 33.00M | 48.00M | 39.00M | 14.00M | 1.00M | 1.00M | 4.00M | 5.26M | 359.00K | 212.00K |
| Pretax Income | -353.00M | -282.00M | -301.00M | -266.00M | 55.00M | -123.00M | -84.71M | — | — | — |
| Income Tax | 0 | 1.00M | 6.00M | 1.00M | 2.00M | — | — | — | — | — |
| Net Income | -353.00M | -283.00M | -307.00M | -267.00M | 53.00M | -123.00M | -84.71M | -49.59M | -53.08M | -17.97M |
| Net Income growth (YoY) | — | — | — | -603.77% | — | — | — | — | — | — |
| EPS (Basic) | -3.29 | -3.14 | -4.15 | -3.71 | 0.76 | -2.24 | -1.93 | -1.43 | -29.03 | -20.80 |
| EPS (Diluted) | -3.29 | -3.14 | -4.15 | -3.71 | 0.71 | -2.24 | -1.93 | -1.43 | -29.03 | -20.80 |
| Shares Outstanding (Basic) | 107.40M | 90.10M | 74.00M | 72.00M | 69.30M | 54.80M | 43.83M | 36.36M | 3.89M | 3.37M |
| Shares Outstanding (Diluted) | 107.40M | 90.10M | 74.00M | 72.00M | 74.00M | 54.80M | 43.83M | 34.62M | 1.83M | 863.98K |
| EBITDA | -376.00M | -320.00M | -332.00M | -274.00M | 58.00M | -121.00M | -85.13M | -51.20M | -50.83M | -16.87M |
| Operating Margin | -156.28% | -127.91% | -290.60% | -250.00% | 14.10% | -158.97% | -591.39% | -656.76% | -3782.09% | — |
| Net Margin | -142.91% | -109.69% | -262.39% | -238.39% | 13.84% | -157.69% | -564.73% | -593.73% | -3756.69% | — |
This table shows 10 annual periods of Arcus Biosciences's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow RCUS's reporting calendar. What is a income statement?